CA2978916A1 - Methods for modulating bone density - Google Patents
Methods for modulating bone densityInfo
- Publication number
- CA2978916A1 CA2978916A1 CA2978916A CA2978916A CA2978916A1 CA 2978916 A1 CA2978916 A1 CA 2978916A1 CA 2978916 A CA2978916 A CA 2978916A CA 2978916 A CA2978916 A CA 2978916A CA 2978916 A1 CA2978916 A1 CA 2978916A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- subject
- disease
- hydrogen
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130144P | 2015-03-09 | 2015-03-09 | |
| US62/130,144 | 2015-03-09 | ||
| PCT/US2016/021344 WO2016144946A1 (en) | 2015-03-09 | 2016-03-08 | Methods for modulating bone density |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2978916A1 true CA2978916A1 (en) | 2016-09-15 |
Family
ID=56879295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2978916A Abandoned CA2978916A1 (en) | 2015-03-09 | 2016-03-08 | Methods for modulating bone density |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180042943A1 (enExample) |
| EP (1) | EP3268009A4 (enExample) |
| JP (1) | JP2018507880A (enExample) |
| KR (1) | KR20170125927A (enExample) |
| CN (1) | CN107530361A (enExample) |
| AU (1) | AU2016229906A1 (enExample) |
| CA (1) | CA2978916A1 (enExample) |
| HK (1) | HK1243646A1 (enExample) |
| IL (1) | IL254197A0 (enExample) |
| MX (1) | MX2017011399A (enExample) |
| SG (1) | SG11201707328SA (enExample) |
| WO (1) | WO2016144946A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| US10919162B2 (en) | 2018-12-26 | 2021-02-16 | Ford Global Technologies, Llc | Systems and methods for efficient power management of modular mobile robot platforms with replaceable batteries |
| DE102020101118A1 (de) | 2019-01-18 | 2020-07-23 | Ford Global Technologies, Llc | Mobile mehrzweckroboter und verfahren zu deren verwendung |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003073991A2 (en) * | 2002-03-01 | 2003-09-12 | Celltech R & D, Inc. | Methods to increase or decrease bone density |
| WO2003080803A2 (en) * | 2002-03-21 | 2003-10-02 | Smithkline Beecham Corporation | Methods of using farnesoid x receptor (fxr) agonists |
| CL2007003035A1 (es) * | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
| JP2012072095A (ja) * | 2010-09-29 | 2012-04-12 | Tokyo Institute Of Technology | 骨形成促進剤 |
| ES2822375T3 (es) * | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
| WO2014021694A1 (ko) * | 2012-08-03 | 2014-02-06 | 서울대학교 산학협력단 | 골 관련 질환 예방 및 치료를 위한 조성물 |
| CN105377870B (zh) * | 2013-05-14 | 2018-04-03 | 英特塞普特医药品公司 | 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物 |
-
2016
- 2016-03-08 JP JP2017547148A patent/JP2018507880A/ja active Pending
- 2016-03-08 SG SG11201707328SA patent/SG11201707328SA/en unknown
- 2016-03-08 EP EP16762337.0A patent/EP3268009A4/en not_active Withdrawn
- 2016-03-08 US US15/556,514 patent/US20180042943A1/en not_active Abandoned
- 2016-03-08 HK HK18103269.8A patent/HK1243646A1/zh unknown
- 2016-03-08 AU AU2016229906A patent/AU2016229906A1/en not_active Abandoned
- 2016-03-08 KR KR1020177027942A patent/KR20170125927A/ko not_active Withdrawn
- 2016-03-08 CN CN201680022614.7A patent/CN107530361A/zh active Pending
- 2016-03-08 MX MX2017011399A patent/MX2017011399A/es unknown
- 2016-03-08 WO PCT/US2016/021344 patent/WO2016144946A1/en not_active Ceased
- 2016-03-08 CA CA2978916A patent/CA2978916A1/en not_active Abandoned
-
2017
- 2017-08-29 IL IL254197A patent/IL254197A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3268009A1 (en) | 2018-01-17 |
| US20180042943A1 (en) | 2018-02-15 |
| SG11201707328SA (en) | 2017-10-30 |
| CN107530361A (zh) | 2018-01-02 |
| IL254197A0 (en) | 2017-10-31 |
| AU2016229906A1 (en) | 2017-09-21 |
| JP2018507880A (ja) | 2018-03-22 |
| KR20170125927A (ko) | 2017-11-15 |
| WO2016144946A1 (en) | 2016-09-15 |
| MX2017011399A (es) | 2018-03-16 |
| HK1243646A1 (zh) | 2018-07-20 |
| EP3268009A4 (en) | 2018-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5990160B2 (ja) | 抗酸化炎症モジュレーターを使用して肥満を処置する方法 | |
| EP3842043A1 (en) | Methods for using fxr agonists | |
| CN106102734B (zh) | 肝内胆汁淤积性疾病的治疗 | |
| EP2902025A1 (en) | Therapeutic agent for dyslipidemia | |
| JP2022541503A (ja) | Ｆｘｒアゴニストを使用した肝疾患の組み合わせ処置 | |
| EP3579827A1 (en) | Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease | |
| CN110352058A (zh) | 相伴给予糖皮质激素受体调节剂和cyp3a抑制剂 | |
| AU2020316740A1 (en) | Treatment comprising FXR agonists | |
| US20180042943A1 (en) | Methods for modulating bone density | |
| Li et al. | Saikosaponin D improves non-alcoholic fatty liver disease via gut microbiota-bile acid metabolism pathway | |
| RU2005112247A (ru) | Новые структуры и композиции, содержащие стеролы и/или станолы и определенные классы противовоспалительных средств, и их применение для лечения или предупреждения сердечно-сосудистого заболевания, лежащих в его основе состояний, включая гиперлипидемию, и других нарушений, при которых воспаление является частью их этиологии или проявления | |
| US20170304336A1 (en) | Combination | |
| JP2022505033A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
| US20130143848A1 (en) | Use of megestrol acetate for improving heart function and the treatment of heart insufficiency | |
| WO2025250918A1 (en) | Novel compositions | |
| US20250171490A1 (en) | Dhea-derived steroids | |
| US20260060948A1 (en) | Methods for treating liver disease | |
| CN107811989A (zh) | 一种瑞舒伐他汀钙药物组合物及其制备方法 | |
| JP2010090094A (ja) | Ｏａｔｐ−ｒ遺伝子発現増強組成物 | |
| JP2025530798A (ja) | エキシコリラントとエンザルタミドを用いて前立腺がんを治療する方法 | |
| CA3204811A1 (en) | Denatonium salt for use in preventing, preventing progression and treating fatty liver diseases | |
| HK1176291A (en) | Use of antioxidant inflammation modulators in manufacture of medicaments for treating obesity | |
| HK40008997A (en) | Inhibition of fibrosis in non-alcoholic fatty liver disease patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220531 |